Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

1&h=537704384&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2889507- 1%26h%3D1377821239%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D2823479- 1%2526h%253D536261162%2526u%253Dhttp%25253A%25252F%25252Fwww.hoththerapeutics.com%25252F%2526a%253Dwww.hoththerapeutics.com%26a%3Dww (678) 570-6791SOURCE Hoth Therapeutics, Inc. NEW Y ...